R. Mehta

发表

Imaging in breast cancer: Diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy

B. Tromberg, N. Shah, A. Cerussi, 2005, Breast Cancer Research.

Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy

B. Tromberg, N. Shah, A. Cerussi, 2007, Proceedings of the National Academy of Sciences.

Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy.

B. Tromberg, N. Shah, A. Cerussi, 2007, Journal of biomedical optics.

Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy

B. Tromberg, A. Cerussi, D. Hsiang, 2011, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

Diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant

B. Tromberg, N. Shah, A. Cerussi, 2005 .

Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment

B. Tromberg, A. Cerussi, D. Hsiang, 2011, Proceedings of the National Academy of Sciences.

Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.

B. Pogue, K. Paulsen, D. Mankoff, 2016, Cancer research.

ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI).

K Paulsen, N M Hylton, A G Yodh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy

Orhan Nalcioglu, Rita S Mehta, O. Nalcioglu, 2008, Cancer.

Risk of a Second Breast Cancer Associated with Hormone-Receptor and HER2/neu Status of the First Breast Cancer

J. Zell, H. Anton-Culver, T. Taylor, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Comparison of breast density measured on MR images acquired using fat-suppressed versus nonfat-suppressed sequences.

Min-Ying Su, Orhan Nalcioglu, Muqing Lin, 2011, Medical physics.

Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer

J. Zell, R. Mehta, H. Sanati, 2009, Anti-cancer drugs.

Effect of taxane‐based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR

M. Su, C. McLaren, J. Chen, 2013, NMR in biomedicine.

LONG-TERM FOLLOW-UP OF BREAST CONSERVING THERAPY IN INFLAMMATORY BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY

D. Hsiang, J. Butler, J. Chen, 2015 .

Long-term Follow-up of Breast-conserving Therapy in Patients with Inflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy

D. Hsiang, J. Butler, M. Su, 2014, The American surgeon.

MRI features of breast cancer: a correlation study with HER-2 receptor.

D. Hsiang, O. Nalcioglu, M. Su, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

S. Paik, G. Tang, J. Costantino, 2015, The Lancet. Oncology.

Independent association of angiogenesis index with outcome in prostate cancer.

E. Small, C. McLaren, H. Kim, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract P5-01-07: Oxyhemoglobin Flare after the First Day of Neoadjuvant Breast Cancer Chemotherapy Predicts Overall Response

A. Cerussi, D. Hsiang, J. Butler, 2010 .

Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.

David Hsiang, Darren Roblyer, Bruce J Tromberg, 2012, Cancer research.

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens

Hannah M. Peterson, B. Tromberg, D. Roblyer, 2020, Breast Cancer Research.

Inflammatory Breast Cancer After Neoadjuvant Chemotherapy: Can Magnetic Resonance Imaging Precisely Diagnose the Final Pathological Response?

O. Nalcioglu, M. Su, R. Mehta, 2008, Annals of Surgical Oncology.

Dramatic Response to Carboplatin, Paclitaxel, and Radiation in a Patient With Malignant Myoepithelioma of the Breast.

R. Mehta, P. Tran, L. Zhuang, 2016, The oncologist.

MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy

Hon J. Yu, O. Nalcioglu, M. Su, 2007, Journal of magnetic resonance imaging : JMRI.

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2015 .

Treatment of Aggressive Metastatic Breast Cancers with Signet-Ring Cell Features

R. Mehta, P. Tran, 2019 .

Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.

R. Mehta, P. Carpenter, T. Schubbert, 2009, Clinical breast cancer.

Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.

R. Mehta, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.

O. Nalcioglu, M. Su, J. Chen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) -> weekly carboplatin and albumin- bound paclitaxel (nab-TC) plus trastuzumab (H) or bevacizumab (B) in patients with large and inflammatory breast cancer (BC): A phase II study

R. Mehta, 2007 .

Trastuzumab in inflammatory breast cancer.

R. Mehta, K. Kong, T. Schubbert, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.

R. Mehta, D. Jackson, T. Schubbert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormone receptor, grade, human epidermal growth factor receptor 2, and topoisomerase II as predictors of response to chemotherapy.

R. Mehta, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of pregnancy associated metastatic hormone and Her-2 receptor positive inflammatory breast cancer: A real challenge

R. Mehta, P. Tran, 2016 .

Pathological Axillary Lymph Node Status in HER-2 Receptor Positive and Negative Breast Cancers

O. Nalcioglu, M. Su, J. Chen, 2008, Annals of Surgical Oncology.

An alternative flow cytometry strategy for peripheral blood dendritic cell enumeration in the setting of repetitive GM-CSF dosing

Kehui Wang, E. Nelson, R. Mehta, 2006, Journal of Translational Medicine.

MRI Measurements of Tumor Size and Pharmacokinetic Parameters as Early Predictor of Response in Breast Cancer Patients Undergoing Neoadjuvant AC-Chemotherapy

Hon J. Yu, O. Nalcioglu, M. Su, 2008 .

Radiation-Associated Angiosarcoma of the Breast: A Case Report and Literature Review

Y. Lyou, R. Mehta, R. Parajuli, 2018, Case Reports in Oncology.

Diagnostic Performance of MRI for Assessing Tumor Response in HER2 Negative Breast Cancer Receiving Neoadjuvant Chemotherapy Is Associated with Molecular Biomarker Profile

D. Hsiang, J. Butler, M. Su, 2012 .

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

G. Hortobagyi, L. Pusztai, W. Barlow, 2021, Clinical Cancer Research.

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

G. Hortobagyi, R. Livingston, W. Barlow, 2019, The New England journal of medicine.

Combination anastrozole and fulvestrant in metastatic breast cancer.

Robert B Livingston, Rita S Mehta, Daniel F Hayes, 2012, The New England journal of medicine.

Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: Clinical response in patients with breast cancer.

R. Mehta, K. Kong, T. Schubbert, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Lesley Fallowfield, Mohammad Jahanzeb, Debra L Barton, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of MRI-Evaluated Neoadjuvant Chemotherapy Response on Change of Surgical Recommendation in Breast Cancer

Min-Ying Su, Orhan Nalcioglu, Rita S Mehta, 2009, Annals of surgery.

Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy1

Hon J. Yu, M. Su, J. Chen, 2015, Translational oncology.

Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without Bevacizumab

Hon J. Yu, O. Nalcioglu, M. Su, 2009, Annals of Surgical Oncology.

Monitoring Breast Cancer Tumor Response At Different Timepoints During Pre-Surgical Chemotherapy with Diffuse Optical Spectroscopic Imaging

B. Tromberg, A. Cerussi, D. Hsiang, 2010 .

Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.

Hon J. Yu, O. Nalcioglu, M. Su, 2009, Radiology.

Long-term outcome of phase II study of biweekly dose-dense AC followed by weekly paclitaxel and carboplatin and trastuzumab (TC {+/-} H) based on HER2 status in large and inflammatory breast cancer (BC).

R. Mehta, D. Jackson, T. Schubbert, 2010 .

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

G. Hortobagyi, R. Livingston, W. Barlow, 2016, British journal of clinical pharmacology.

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

G. Hortobagyi, L. Pusztai, W. Barlow, 2023, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Abstract PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial

G. Hortobagyi, L. Pusztai, W. Barlow, 2021 .

Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS

O. Nalcioglu, M. Su, K. Nie, 2011, NMR in biomedicine.

Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment

Stefan A. Carp, Brian Pogue, Bruce J. Tromberg, 2018, Journal of biomedical optics.

Prediction of breast cancer molecular subtypes on DCE-MRI using convolutional neural network with transfer learning between two centers

M. Su, D. Chow, P. Chang, 2020, European Radiology.

Biomarker conservation in primary and metastatic epithelial ovarian cancer.

R. Burger, P. Disaia, I. Yu, 2000, Gynecologic oncology.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2017, Annals of Surgical Oncology.

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

J. Zell, H. Anton-Culver, T. Taylor, 2009, Breast Cancer Research.

NON-INVASIVE MEASUREMENT OF DEEP TISSUE TEMPERATURE CHANGES CAUSED BY APOPTOSIS DURING BREAST CANCER NEOADJUVANT CHEMOTHERAPY: A CASE STUDY.

So Hyun Chung, Bruce J Tromberg, Arjun G Yodh, 2011, Journal of innovative optical health sciences.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

G. Tang, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

James A Young, Norman Wolmark, Rita S Mehta, 2012, The New England journal of medicine.

The Prognostic Value of Tumor Markers in Patients with Glioblastoma Multiforme: Analysis of 32 Patients and Review of the Literature

R. Clatterbuck, M. Zahurak, H. Brem, 2001, Journal of Neuro-Oncology.

Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.

Hon J. Yu, S. Feig, D. Hsiang, 2011, Radiology.

Triple-negative breast cancer: MRI features in 29 patients.

O Nalcioglu, O. Nalcioglu, M. Su, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors Associated With Success of the Extreme Drug Resistance Assay in Primary Breast Cancer Specimens

M. Mayo, O. Tawfik, B. Kimler, 2004, Breast Cancer Research and Treatment.

A Prospective Blinded Study of the Predictive Value of an Extreme Drug Resistance Assay in Patients Receiving CPT-11 for Recurrent Glioma

T. Cloughesy, R. Parker, R. Mehta, 2004, Journal of Neuro-Oncology.

Pathological complete response in triple negative poorly differentiated invasive ductal breast carcinoma detected during pregnancy.

O. Nalcioglu, M. Su, J. Chen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis of Breast Cancer Using Radiomics Models Built Based on Dynamic Contrast Enhanced MRI Combined With Mammography

M. Su, J. Chen, Meihao Wang, 2021, Frontiers in Oncology.

Benign Metastasizing Leiomyoma to the Lung and Spine: A Case Report and Literature Review

R. Mehta, R. Parajuli, K. Lane, 2019, Case Reports in Oncology.

Characterization of Pure Ductal Carcinoma In Situ on Dynamic Contrast-Enhanced MR Imaging: Do Nonhigh Grade and High Grade Show Different Imaging Features?

Min-Ying Su, Orhan Nalcioglu, Muqing Lin, 2010, Journal of oncology.

Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.

D. Hsiang, J. Butler, M. Su, 2007, Archives of surgery.

The Predictive Value of Sentinel Lymph Node Biopsy in Locally Advanced Breast Cancer Patients who Have Undergone Neoadjuvant Chemotherapy

D. Hsiang, J. Butler, M. Su, 2007, The American surgeon.

Deep Learning-based Automatic Diagnosis of Breast Cancer on MRI Using Mask R-CNN for Detection Followed by ResNet50 for Classification.

M. Su, K. Nie, J. Chen, 2023, Academic radiology.

Automatic Detection and Segmentation of Breast Cancer on MRI Using Mask R-CNN Trained on Non-Fat-Sat Images and Tested on Fat-Sat Images.

Yang Zhang, Peter Chang, Daniel Chow, 2020, Academic radiology.

BI-RADS Reading of Non-Mass Lesions on DCE-MRI and Differential Diagnosis Performed by Radiomics and Deep Learning

M. Su, J. Chen, Meihao Wang, 2021, Frontiers in Oncology.

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology

D. Hsiang, J. Butler, M. Su, 2014, Journal of surgical oncology.

Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

R. Mehta, T. Schubbert, 2008, Journal of the National Cancer Institute.

Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Hon J. Yu, S. Feig, D. Hsiang, 2012, Clinical breast cancer.

Title Diagnostic Performance of MRI for Assessing Tumor Response in HER 2 Negative Breast Cancer Receiving Neoadjuvant Chemotherapy Is Associated with Molecular Biomarker

Hon J. Yu, D. Hsiang, J. Butler, 2012 .

Measurement of Volumetric and Vascular Changes with Dynamic Contrast Enhanced MRI for Cancer Therapy Monitoring

Hon J. Yu, Jun Wang, O. Nalcioglu, 2002, Technology in cancer research & treatment.

Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay

C. McLaren, R. Parker, I. Yu, 2001, Breast Cancer Research and Treatment.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

C. McLaren, R. Parker, R. Mehta, 2002, Gynecologic oncology.

Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.

B. Monk, R. Burger, P. Disaia, 2005, Gynecologic oncology.

Undergoing Neoadjuvant Chemotherapy Pathologic Complete Response in Breast Cancer Patients Baseline Tumor Oxygen Saturation Correlates with a

Bruce J. Tromberg, David Hsiang, Darren Roblyer, 2012 .

Detection of choline signal in human breast lesions with chemical‐shift imaging

Hon J. Yu, O. Nalcioglu, M. Su, 2008, Journal of magnetic resonance imaging : JMRI.

Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy.

R. Mehta, M. P. Shieh, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantification of Choline-containing Compounds in Malignant Breast Tumors by 1H MR Spectroscopy Using Water as an Internal Reference at 1.5 T

Hon J. Yu, O. Nalcioglu, M. Su, 2006, Magnetic Resonance Materials in Physics, Biology and Medicine.

Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.

David Hsiang, Bruce J Tromberg, Albert E Cerussi, 2010, Academic radiology.

Coregistration of Dynamic Contrast Enhanced MRI and Broadband Diffuse Optical Spectroscopy for Characterizing Breast Cancer

Min-Ying Su, David Hsiang, Orhan Nalcioglu, 2005, Technology in cancer research & treatment.

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens

Hannah M. Peterson, B. Tromberg, D. Roblyer, 2020, Breast Cancer Research.

Development of U-Net Breast Density Segmentation Method for Fat-Sat MR Images Using Transfer Learning Based on Non-Fat-Sat Model

Min-Ying Su, Rita S. Mehta, Wei-Ching Lin, 2021, Journal of Digital Imaging.

Breast cancer differential diagnosis using diffuse optical spectroscopic imaging and regression with z-score normalized data

Bruce J. Tromberg, Arjun G. Yodh, David R. Busch, 2021, Journal of biomedical optics.

Breast Tumor Biochemical Responses to Neoadjuvant Chemotherapy Can Be Observed Using Diffuse Optical Spectroscopy

B. Tromberg, N. Shah, A. Cerussi, 2006 .

Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.

Min-Ying Su, Muqing Lin, Hon Yu, 2013, Magnetic resonance imaging.

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology

D. Hsiang, J. Butler, M. Su, 2014, Journal of surgical oncology.

Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.

Min-Ying Su, Orhan Nalcioglu, Hon J. Yu, 2006, Technology in cancer research & treatment.

Detection of choline signal in human breast lesions with chemical‐shift imaging

Hon J. Yu, O. Nalcioglu, M. Su, 2008, Journal of magnetic resonance imaging : JMRI.

Continued Exploration of Bevacizumab in Breast Cancer

M. Su, R. Mehta, 2009, Annals of Surgical Oncology.